Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-75 years,~* BMI 25-35 kg/m2,~* WHO criteria for type 2 diabetes fasting plasma glucose\>=7.0 mmol/l on at least 2 separate occasions,~* C-peptide\>0.2 nmol/l~Exclusion Criteria:~* plasma glucose \< 6.1 or \>10 mmol/l after the screening period~* cardiac heart failure~* diagnosed coronary heart disease~* severe aortic, mitral or tricuspidal valve disease~* blood pressure \> 160/ 100 mg Hg~* any previous or present hepatic (GT \>100, alanine amino transferase \>3 x upper limit of the reference range) or renal (S-creatinine \> 130) disease~* pregnancy or lactation~* proliferative retinopathy~* microalbuminuria~* subjects with history of lactate acidosis~* symptomatic polyneuropathy~* antidiabetic medication~* changes in antihypertensive medication or beta-blockers in medication~* metal objects in region of imaging~* anemia with Hb \< 100 in mean or \< 90 in women~* oral corticosteroid treatment

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo, 2 tablets per day
- Metformin (Type: ACTIVE_COMPARATOR): 500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
- Rosiglitazone (Type: ACTIVE_COMPARATOR): 2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).